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Insulin-like growth factor I (IGF-I) is a polypeptide hormone produced mainly by the liver in response to the
endocrine GH stimulus, but it is also secreted by multiple tissues for autocrine/paracrine purposes. IGF-I is partly
responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant,
anti-inflammatory and cytoprotective actions).
IGF-I is a closely regulated hormone. Consequently, its logical therapeutical applications seems to be limited to
restore physiological circulating levels in order to recover the clinical consequences of IGF-I deficiency, conditions
where, despite continuous discrepancies, IGF-I treatment has never been related to oncogenesis. Currently the best
characterized conditions of IGF-I deficiency are Laron Syndrome, in children; liver cirrhosis, in adults; aging including
age-related-cardiovascular and neurological diseases; and more recently, intrauterine growth restriction.
The aim of this review is to summarize the increasing list of roles of IGF-I, both in physiological and pathological
conditions, underlying that its potential therapeutical options seem to be limited to those proven states of local or
systemic IGF-I deficiency as a replacement treatment, rather than increasing its level upper the normal range.
Keywords: Laron syndrome, Liver cirrhosis, Aging, Oxidative stress, GH/IGF-I axis, Mitochondrial dysfunction, Cellular
protection, Growth, Cancer protectionIntroduction
Insulin-like growth factor I (IGF-I) is a 70 aa polypeptide
hormone with endocrine, paracrine, and autocrine
effects. It shares >60% homology with IGF-II and by
50% homology with proinsulin structures [1].
IGFs were first described in 1957 by Salmon and
Daughaday [2] when they noted that direct addition of
growth hormone (GH) to costal cartilage from hypophy-
sectomized rats in vitro did not significantly stimulate
growth (measured by radioactive sulfate uptake). Con-
sistently, serum from these hypophysectomized rats was
also ineffective. However, normal rat serum stimulated
the in vitro uptake of sulfate into costal cartilage from
hypophysectomized rats. These results demonstrated the
existence in serum of a “sulfation factor” that stimulated
incorporation of 35Sulfate by costal cartilage.
In parallel, Froesch et al. described the non-suppressible
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distribution, and reproduction in any mediumcomponents (NSILA I and II) by the fact that they stimu-
lated glucose uptake into isolated rat adipocytes, sharing
“insulin-like” activity, while anti-insulin antibodies were
not able to abrogate their hypoglycemic effects [3].
At the same time, other investigators found some
other roles for these polypeptides. Among all, their mito-
genic capability, that moved them to propose the term
“fraction with multiplication stimulating activity” [4].
Only when Daughaday et al. pointed out that the sulfa-
tion factors were “identical with or very similar to the
smaller molecular weight component of the non-
suppressible insulin-like activity” in 1972, a new nomencla-
ture was proposed for these two molecules: somatomedin
A and C, denoting substances under control and media-
ting the effects of GH [5].
Finally, a more extensive research on NSILAs/
somatomedins carried out by Rinderknecht and Humbel
[6,7] culminated with the discovery that those molecules
had identical amino acid sequences to “two forms of an
insulin-like hormone whose effects on cell and tissue
growth predominate over those on metabolic para-
meters” [8]. Therefore, accordingly to their structuralioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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“insulin-like growth factor I and II” (IGF-I and II), mole-
cules that also fulfill all the criteria of a somatomedin:
1) they possess insulin-like activity in the presence of in-
sulin antibodies [3,9]; 2) they are sulfation factors [9,10];
3) they could act as mitogens [9,11]; and 4) at least, IGF-
I is growth-hormone dependent [5].
The consensus about their nomenclature [12] together
with the milestone in the discovery of their amino acid
sequences, which made possible the subsequent recom-
binant synthesis [8], opened the door to many new areas
of research, and boosted the number of articles from
that moment up to more than 32,500 works currently
indexed in PubMed.
This historical perspective provides us a list of actions
carried out by IGF-I, among others: tissue growth and
development, insulin-like activity, proliferative, pro-sur-
vival/anti-aging, antioxidant, etc.
As an hormone with a wide range of physiological roles,
IGF-I levels must be strictly controlled, as it has been
demonstrated from in vivo results: six forms of high affin-
ity IGF binding proteins (IGFBPs 1 to 6), either promoting
or inhibiting IGF-I actions; a yearly increasing list of
IGFBPs proteases; allelic variations and an alternative spli-
cing are some of the mechanisms by which IGF-I is tightly
maintained in a close physiological range (~286.1±52.4
ng/mL, adults between 21–40 years old) [13,14].
On the other hand, majority of IGF-I actions are
mediated through the union of IGF-I to its putative re-
ceptor, IGF-IR, a tyrosine kinase that is one of the most




Figure 1 Schematic structures of IGFs and their receptors. Resemblanc
IGFs are able to bind to their own receptors (preferently) but also to Insulin
components from both IR and IGF-IR. * IGF-II can also interact with IGF-IR,among others: mTOR, MAPK, GSK3β, FOXO, HDM2,
Grb2 and Shc systems, all of them closely related with
cell survival, growth and proliferation [15-17]. However,
IGF-I can also bind to the insulin receptor (with a lower
affinity), as a secondary via through which this hormone
mediates some of its metabolic functions [6], due to
their high homology. Complementarily, insulin can also
bind to IGF-IR with a lower specificity than insulin re-
ceptor (Figure 1).
Under this scenario, a review about the increasing list
of IGF-I roles, both in physiological and pathological
conditions, and its therapeutical potential, arises as a
promising field of work.
Physiological roles of IGF-I
IGF-I is a relevant hormone both in embryological and
postnatal states. Although it is mainly produced by the
liver, virtually every tissue is able to secrete IGF-I for
autocrine/paracrine purposes [18].
Pituitary (GH) and liver (IGF-I) establish negative
feedback mechanisms common to any other endocrine
gland. The pituitary somatotrophs (GH-secreting cells)
are under a delicate controlled balance between stimula-
tory growth horomone-releasing hormone and inhibitory
somatostatin, both generated by the hypothalamus as a
result of systemic and cortical neurogenic, metabolic,
and hormonal factors [19]. In another hand, IGF-I inhi-
bits GH secretion acting on the hypothalamus by two
feedback mechanisms: firstly, inhibiting GH gene expres-
sion [20] and secondly by stimulating the secretion of














es between Insulin and IGFs allow them to cross-interactions by which
receptor (IR) with a lower specificity. The hybrid receptor shares
hybrid receptor and insulin receptor, with a lower affinity.
Figure 2 GH/IGF-I axis and targets. Pituitary GH interacts with GH receptors in hepatocytes increasing IGF-I secretion for endocrinological
purposes in different organs, although an autocrine/paracrine IGF-I production by those organs is also present.
Puche and Castilla-Cortázar Journal of Translational Medicine 2012, 10:224 Page 3 of 29
http://www.translational-medicine.com/content/10/1/224Secreted GH can exist in both free and bound states
by the GHBP (the secondary domain of the GH recep-
tor) [19]. Also, activation of liver GH receptor, promotes
IGF-I synthesis which, in turn, is released to the circula-
tion and can be found in its free form but mainly bound
to IGFBPs (overall IGFBP-3, which binds ~90% of circu-
lating IGF-I) [23].
The role of IGF-I in physiological conditions is still
being uncovered and continuously unfastened from GH
actions as an independent, self-sufficient peptide. For ex-
ample, it is known that GH and nutrition are the major
factors that regulate hepatic IGF-I expression, as well as
in other organs [24,25]. However, in some other tissues,
IGF-I expression appears to be regulated by tissue spe-
cific trophic factors, as for example in uterus, where
estrogens (and not GH) stimulate IGF-I expression [26],
while follicle stimulating hormone is a major IGF-I regu-
lator in ovary [27].
In an attempt to provide a coherent and integrated re-
view of certain physiological conditions where the role
of IGF-I has been well established, we have summarized
them in this review (cfr. Figure 2).Body growth
IGFs have been shown to play a very important role in
fetal growth and differentiation [24,28,29], although their
pattern of expression and abundance varies among
organs. For instance, in fetal liver, kidney and heart are
lower than IGF-II, while they progressively increase after
birth (as serum IGF-I concentration does). However, ex-
pression of IGF-I in fetal lung, muscle, and stomach is
higher than it is postnatally [29].Of interest, while the actions of IGF-I after birth are
being continuously recognized, the physiologic role of
IGF-II is still poorly understood at this stage [1,30].
Interestingly, it was reported that GH is not required for
normal intrauterine growth, a finding supported by evi-
dence that GH deficiency/insensitivity does not associate
with a significant reduced size at birth [31-35]. In con-
trast, inactivating mutations of IGF-I or its receptor,
have clearly established that IGF-I is a major regulator
of intrauterine growth [36-41]. Thus, these findings sug-
gest that the stimulatory role of IGF-I on intrauterine
growth is GH-independent.
With this perspective, Daughaday et al. [5,42] pro-
posed the somatomedin hypothesis for the postnatal
growth, where GH stimulated skeletal growth by stimu-
lating liver production of IGF-I, which in turn promotes
longitudinal bone growth in an endocrine manner. How-
ever, a noteworthy direct action of GH on bone growth
has also been reported [43,44]. Nevertheless, the discov-
ery of an extra-hepatic IGF-I production in the following
years [18,45], made it necessary to spand the conception
of the GH/IGF-I axis, being well accepted nowadays that
pituitary GH is able to induce IGF-I synthesis in both
liver (~75%) and other tissues [23,46,47], which subse-
quently, is able to act in an endocrine/paracrine/auto-
crine manner.
So, taking into account all these data, we can conclude
that both GH and IGF-I has independent and synergic
effects in promoting postnatal body growth. This idea
was also confirmed by comparing the weight of trans-
genic mice with GH receptor inactivation, IGF-I knock-
out and the double inactivation [36]. As expected,
double knockout mice presented a more severe
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(~20% more).
Finally, GH and IGF-I (both liver/endocrine and lo-
cally produced) are essential for normal body growth.
The role of other molecules for this control is also im-
portant and may increase the complexity in the under-
standing of these mechanisms. Acid-labile subunit (ALS)
and IGFBP-3 are two proteins that bind IGF-I (~90% of
total serum IGF-I) in a ternary complex which trans-
ports and prolong IGF-I half-life in circulation [23]. Al-
though the liver is also the principal source of
circulating IGFBP-3 and ALS, other tissues have been
proposed to produce these factors [48,49]. The import-
ance of IGFBP-3 relies also on its capability to act inde-
pendently from IGF-I, regulating growth, apoptosis and
metabolism of target cells [50-52]. Therefore, the expres-
sion of ALS and IGFBP-3 in non-hepatic tissues and
possible IGF-I-independent effects of IGFBP-3, should
be considered when analyzing findings. To go through
IGFBP-3 roles/effects in depth the review by Ohlsson C
et al. is recommended [23].
Central nervous system (CNS) development
Although the action mechanisms of IGF-I in neurons
have not been fully elucidated, it has been shown that
IGF-I stimulates the autophosphorylation of IGF-IR [53]
in a different manner to insulin [54]. Furthermore, as it
will be further discussed, we have reported a neuropro-
tective role for IGFs associated to mitochondrial protec-
tion and antioxidant defenses in aging animals [55-58].
Both mechanistic pathways, that may be linked, are cur-
rently being studied in more detail.
IGF-I is harmonically produced by peaks that coincide
with periods of neuron progenitor proliferation and dif-
ferentiation, neuritic outgrowth (increasing the number
of dendrites, axonal cones, synapse number. . .) or post-
injury conditions [59]. However, the possibility of IGF-I
to influence neural stem cells (NSC) is still on debate
despite the fact that IGF-I and IGF-IR are expressed in
cultured NSC [60,61], and that in response to IGF-I, cul-
tured NSC proceed toward specific lineages, such as
neurons [62] or oligodendrocytes [63].
Interestingly, not only neural-produced IGF-I is
involved in these processes. It was first reported 20 years
ago that systemic IGFs could cross the blood–brain bar-
rier (BBB), when labeled IGFs were infused into the
common carotid arteries of adult rats, and they were
later on detected in the choroid plexus, median emi-
nence, brain arterioles, and parenchyma [64]. In fact,
this work was based on previous data confirming the
presence of IGF-I receptors in brain capillary endothelial
cells (which constitute the BBB), and their role in intern-
alizing IGFs to the CNS from the circulation [65,66]. A
more recent work by Torres-Aleman’s group, elegantlydemonstrated that this process is initiated by the release
of glutamate at active regions, triggering two secondary
processes: a vasodilation to increase local serum IGF-I
availability and an increased activity of matrix metallo-
protease 9, together with cleavage from IGFBP-3. The
combined action of these events results in an increased
local availability of free serum IGF-I, which is then
transported by transcytosis using an endothelial trans-
porter (lipoprotein related receptor 1) dependent mech-
anism [67]. This research may shed light on previous
data identifying liver-derived IGF-I as one of the main
factors in regulating the clearance of brain amyloid-β
(Aβ) levels [68] and its potential implications in Alzhei-
mer’s Disease (what will be further discussed in III.4.3.).
However, it is noteworthy that there is no significant
correlation between serum and cerebrospinal fluid IGFs
concentrations [69] and therefore, it seems that systemic
IGFs are not a major source of IGFs for CNS.
On the other hand, little is known about those factors
and mechanisms that regulate IGF-I expression in the
brain, but there is evidence, however, that growth factors
(i.e. GH, epidermal growth factor, basic fibroblast growth
factor) [70-72], nutrition [73,74], and injury (hypoxic/is-
chemic, stereotactic, electrolytic and cryogenic injuries,
as well as induced demyelination and experimental auto-
immune encephalomyelitis) [75-81], influence its in vivo
brain expression. Nevertheless, IGF-I mRNA abundance
is reduced in the brain of hypophysectomized rats and,
intracerebral infusion of GH restores IGF-I mRNA to
80% of normal levels [70], which points out that GH has
a clear role in modulating brain IGF-I.
Additionaly, IGF-I may promote proliferation and/or
survival of oligodendrocytes and their precursors, but it
also could be involved in the modulation of BBB perme-
ability [81]. The latter would limit accessibility of T lym-
phocytes and soluble destructive immune factors to the
brain. Other possibilities are also plausible, as for in-
stance, IGF-I may influence the peripheral immune reac-
tion, what in turn could reduce CNS inflammation,
demyelination, and BBB permeability [82]. These find-
ings, taken together with the neuroprotective actions of
IGF-I [55,56], suggest that astrocytes are relevant in
ameliorating brain injury.
In another hand, in vivo experiments with transgenic
mice have clarified some aspects about the topic. Trans-
genic (Tg) mice that overexpress IGF-I in the brain exhibit
postnatal brain overgrowth without anatomic abnormality
(up to 85%) via an increase in cell number [83] and mye-
lination [84]. A complementary experiment [83] excluded
the possibility of GH in directly promoting these effects,
since GH-overexpressing Tg mice did not exhibit those
changes. However, as stated before, a role for GH in brain
growth cannot be underestimated, since GH-deficient
mice have significantly smaller brains than normal mice
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pression barely survive postnatally. Survivals have very
small brains (−60% of normal size) but remain morpho-
logically normal [85]. These brains are characterized by a
paucity of white matter owing to markedly decreased mye-
lination [86] and an apparent decrease in the number of
axons [85].
These IGF-I actions, taken together with its neuropro-
tective effects following CNS and peripheral nerve in-
jury, suggest that it may be of therapeutic benefit in a
wide variety of disorders affecting the nervous system.Liver regeneration
The liver is the main source of circulating insulin-like
growth factor I, accounting for ~75% of circulating IGF-I
levels secondary to the GH stimulation on hepatocytes
[23,46,47]. Of interest, although liver-derived IGF-I has
endocrine effects on extrahepatic tissues, there are only few
data regarding local effects of this hormone in the liver [87]
probably due to the very low amount of IGF-I receptors on
the hepatocytes membrane [46,88,89]. However, there are
IGF-I receptors on the nonparenchymal cells [89,90] and it
has been reported that IGF-I stimulates both DNA synthe-
sis [91,92] and the production of hepatocyte growth factor
(HGF) in hepatic stellate cells in vitro [87].
The lack of IGF-I receptors on hepatocytes would also
mean that liver-derived IGF-I would be unable to stimu-
late liver growth during adulthood. Accordingly, mice
with liver-specific IGF-I deficiency, instead of displaying
decreased hepatic growth, showed disproportionally
large livers, likely due to direct stimulation by an unsup-
pressed GH secretion [47,93]. In line with this finding,
GH receptor deficient mice have reduced relative liver
weight [94], and transgenic mice overexpressing GH pre-
sented disproportional growth of the liver, whereas this
is less apparent in mice overexpressing IGF-I [95,96].
Nevertheless, during liver regeneration, where it is
required an explosive burst of hepatocyte renewal (i.e.
after partial hepatectomy), IGF-I may play a role in sup-
porting hepatocyte proliferation and accelerating DNA
synthesis [97,98], together with IL-6, TNF-α, HGF and
TGF-α/EGF [99,100]. It remains unknown why IGF-I
stimulates liver regeneration more effectively than
growth of intact liver.Gametogenesis
Ovarian folliculogenesis
The process of folliculogenesis can be divided into three
developmental phases: I) preantral follicle growth: prim-
ordial to primary follicle transition, and formation and
growth of secondary follicles; II) basal antral follicle
growth: antrum formation and development of early an-
tral follicles to the gonadotrophin-dependent stage; andIII) terminal antral follicle growth: development of antral
to preovulatory follicles [101].
The involvement of the IGF system as intraovarian
regulators of folliculogenesis has been intensively studied
in a variety of mammal species, and it is now established
that the ovary is a site of IGF-I gene expression and re-
ception [102]. However, this huge amount of data could
be somehow distractive since different species may pro-
duce distinct IGFs (or their relative binding proteins and
receptors) at different stages of follicular development.
For this reason, in this review, we will focus on murine
and primate data.
In primate, mRNA expression patterns of IGF-I and its
putative receptor have been deeply studied during follicu-
logenesis. IGF-I is expressed in primordial follicles, pri-
mary follicles, secondary follicles and growing antral
follicles (oocyte and theca), but not in preovulatory folli-
cles (mural granulose and theca) [101]. Of interest, IGF-IR
mRNA is temporally consistent with the IGF-I expression,
except from the mural granulose cells, where IGF-IR pro-
duction is preserved, suggesting a paracrine/endocrine de-
pendence for the IGF-I effects at this level [101].
The lack of information regarding the role of IGFs in a
specific time point of human folliculogenesis, hinder its
correlation with the expression patterns of IGF-I. Fortu-
nately, murine models provide us a useful tool to eluci-
date its possible implications. This approach suggest that
IGF-I may play a role at different stages of follicular de-
velopment: a) initiation of growth of the primordial fol-
licle; b) at a secondary follicle stage, IGF-I may be
involved on induction of FSH-R expression on granulose
cell and their differentiation, theca cell survival and cor-
tical granules formation in oocytes [103-106]; and c) at
antral follicular stage, IGF-I may increase follicle sensi-
tivity to gonadotrophin, oocyte maturation and LH-R ex-
pression in granulose and theca cells enhancing their
proliferation and steroidogenic activity [107-111]. In
humans, IGF-I also stimulates vascular endothelial
growth factor production by granulose cells [112].
Despite recent progresses, the precise mechanisms
underlying ovarian follicular growth are not yet fully elu-
cidated. In most mammalian species studied, although
GH and IGFs do not appear to be required for primor-
dial to primary follicles transition, they are responsible
for promoting secondary follicle growth and antrum for-
mation. In brief, GH enhances the development of small
antral follicles to the gonadotrophin-dependent stages
and stimulates oocyte maturation, whereas IGFs increase
granulose cell proliferation, steroidogenesis and oocyte
growth in most mammalian species [101].
Testicular function
Although it is well established that testicular function is
mainly controlled by the gonadotropins LH and FSH
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locally produced factors as important key regulators of
testicular function [115]. Among those, IGF-I has been
reported to be a potent candidate due to its para/autocrine
functions. Immunostainable IGF-I has been found in adult
human testes [116]. Cultures of Sertoli and Leydig cells
from adult rats and immature pigs secrete immunoreac-
tive IGF-I into the medium, and this secretion is enhanced
by FSH (Sertoli cells) or LH (Leydig cells) [117,118]. IGF-
IR has also been found on human, pig, and rat Leydig cells
[119-121], where it enhances the differentiated functions
of Leydig cells [122,123].
The crucial role of IGF-I in the development and func-
tion of Leydig cells was obtained from studies in IGF-I
knockout mice [124]. The testes of these animals were
reduced in size and although epididymides were overall
nearly allometric to the reduced body weight, the distal
regions of the duct, vas deferens, seminal vesicles, and
prostate were vestigial. These transgenic mice showed
significantly reduced plasma testosterone levels (18% of
normal) [124] and the IGF-I deficiency was correlated
with an ultrastructural analysis of mutant Leydig cells
revealing a significant developmental delay, with fewer
and smaller Leydig cells than normal. Importantly, it is
noteworthy that those reduced testosterone levels in
serum were inadequate for perinatal androgenization.
And secondly, androgen deficiency in the mutants can
be correlated with an apparently retarded differentiation
of Leydig cells (in concrete, their second phase) [124].
In vitro studies also suggested a relationship between
IGF-I and LH-androgen production in rodents [125],
through a direct effect on Leydig cells.
Consistently, a large number of studies have previously
suggested that the IGF system is involved in mammalian
reproductive functions [108,126,127]. First, it has been
emphasized the importance of insulin receptor family
for the induction of testicular differentiation by Sry-
dependent processes [128]. In addition, IGF-I regulates
the expression of key steroidogenic enzymes during pre-
natal development, which in turn lead to establishment
of the male phenotype and fertility [129]. Moreover,
male gonads cultured in the presence of IGF-I increased
testosterone production during testicular development
[130]. Postnatally, in vitro studies have also demon-
strated that the IGF-I regulates the expression rate of
genes encoding steroidogenic enzymes that involved in
the biotransformation of steroid hormones in the testis
[131-133]. Secondly, a role for IGF-I on sperm number
has been reported since in IGF-I deficient mice there is
a dramatic reduction of sperm number [124]. Moreover,
the vast majority of these males that were caged with
wild type females did not exhibit mating behavior.
In another hand, it is notable that the role of GH, if
any, on the regulation of intratesticular IGF-I may notbe significant, since GH receptor gene may not be
expressed in the testis [134,135] and GHI animals are
fertile (normal steroidogenesis and spermatogenesis)
[136,137]. Interestingly, despite GH deficiency and low
serum IGF-I concentration, they exhibit normal levels of
testicular IGF-I [119]. Thus, in addition to being appar-
ently GH-independent, the testicular functions of IGF-I
seem to be served by its local production (autocrine/
paracrine action) without a major endocrine contribu-
tion by the circulating form of this factor.
Kidney development and function
Several lines of evidence support the role of the GH/
IGF-I system in normal kidney development and func-
tion. IGFs, IGFBPs and IGF receptors (along with GH
receptors) are all expressed in specific locations along
the nephron, suggesting that IGFs have paracrine and
autocrine actions at these sites [138,139].
Both IGF-I and the IGF-IR are expressed in glomerulus
development being their patterns of expression disrupted
in animal models and in human examples of renal disease
[140]. Indeed, it has been demonstrated a role for IGF sig-
naling in maintaining glomerular integrity, by preserving
podocytes and the glomerular basement membrane from
damage. Consistently, IGF-I administration to rodents
increases kidney growth, renal blood flow and glomerular
filtration rate (GFR) [138,141,142], and similarly, GH and
IGF-I also increase renal blood flow and GFR in humans
[143], suggesting that IGF-I may be a physiologic regulator
of renal function.
Furthermore, a possible role for the IGF system in
compensatory renal growth was proposed since renal
IGF-I levels are increased in the remaining kidney fol-
lowing uninephrectomy and compensatory renal growth
[144] in an age-dependent manner [145]. However, by
using IGF-I deficient mice, it has been recently reported
that uninephrectomy in these mice induces a significant
and proportional increase in renal mass, as compared to
normal mice, despite markedly decreased kidney IGF-I
levels and no significant changes in receptor phosphoryl-
ation [146]. Therefore, the implications of IGF-I in this
process may be elucidated in following years.
Cardiovascular development
Cardiovascular system is an important target organ for
GH and IGF-I actions. There is evidence that IGF-I and
its receptor are expressed in the myocardium and both
aortic smooth muscle and endothelial cells [45,147-149],
being all of them more sensitive to IGF-I than to insulin
[150,151]. In addition, cardiac IGF-I production
increases in response to GH [45]. Consequently, there
are different possibilities of direct actions of GH as well
as endocrine or autocrine/paracrine effects of IGF-I on
the cardiovascular system.
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tor [152], and that this effect may be partly mediated by
increased NO release from the endothelium [153,154]. Ac-
cumulating evidence would also suggest that insufficient
IGF-I levels play a role in vascular diseases such as athero-
sclerosis and restenosis [155], what will be discussed in
further sections (cardiovascular diseases).
Immune modulation
The potential relationship between immune function
and growth factors such as IGF-I has remained poorly
characterized until recently. However, the realization
that diverse regulatory pathways often converge, moti-
vated a number of studies that eventually demonstrated
the importance of GH, IGF-I, and IGF-IR in many pro-
cesses of immune function [156].
Complex interactions between cytokines and growth
factors, including IGF-I, has been properly reviewed by
O’Connor et al. [157]. In brief, pro-inflammatory cyto-
kines seem to damp several components of the IGF-I
pathway. Many of the cytokines share common signaling
components, such as Erk1/2 MAPK.
The role of IGF-I on thymus development and func-
tion, hematopoiesis and immune system reconstitution
is well documented [158-161].
The role of IGF-I on different immune cell lineages
has also been reported. Both IGF-I plays important roles
in T lymphocytes development and function. Specific-
ally, IGF-I can increase the number of CD4+CD8+ im-
mature T cells in rat thymus and spleen [162], promotes
T cell survival [163], proliferation, chemotaxis and mat-
uration, and blocks spontaneous and induced pro-
grammed cell death [163,164], although it has also been
reported to block IL-2-dependent lymphocyte growth
and function [165]. The possibility for IGF-I to deter-
mine how T-cell compartments are filled throughout life
remains an open question. However, given the import-
ance of IL-7 in that process and how IGF-I potentiates
the actions of IL-7 in pro-B cell expansion [166], a simi-
lar influence on T cells seems likely.
Aging rodents exhibit diminished responsiveness to
pathogens. This shift is associated with reduced cellular-
ity and significant thymus involution [167,168]. As will
be further discussed in section “Aging and age retaled
diseases”, IGF-I and GH levels also decrease with aging
(somatopause) [169], reason why a potential strategy for
reversing these senile changes in thymic vitality may in-
volve administration of either GH or IGF-I, which have
been examined for their potential to expand T-cell
populations in animals [170].
B cells play diverse roles in immune function by virtue
of their further differentiation into immunoglobulin-
secreting plasma cells, generation of cytokines, and their
importance in antigen presentation. IGF-I has beenreported to drive B-cell differentiation, to enhance IL-7-
dependent B-cell proliferation in parallel with c-kit lig-
and [171], as well as to potentiate IL-7 promotion of
pro-B-cell expansion [166]. When administered in vivo,
IGF-I also enhances the population of intrasplenic B
cells through increased proliferation of mature cells
[172,173] together with an influence on antibody expres-
sion and class switching by plasma cells [174].
Human macrophages and granulocytes are also sensi-
tive to IGF-I by displaying IGF-IR [156]. It was docu-
mented that IGF-I attenuated spontaneous apoptosis in
these populations [175].
Finally, neutrophils seems to be a potential target for
IGF-I actions, since it was able to delay Fas-mediated
apoptosis through the PI3K pathway. Moreover, this ef-
fect was conserved even in the presence of pro-apototic
cytokines, suggesting that it may play a dominant role,
even within the context of an active inflammation [156].
Conditions of IGF-I deficiency
An increasing list of animal models has been reported
highlighting the role of this molecule in many different
organs and systems. In this review, we will focus on the
best characterized models of IGF-I deficiency, where the
substitutive therapy may be an effective strategy.
Intrauterine growth restriction (IUGR)
Fetal growth is a complex process involving maternal,
placental, and fetal factors from genetic, environmental,
and nutritional nature. Intrauterine growth restriction is
an important obstetric issue affecting ~5% of pregnan-
cies and refers to a fetus that has not reached its growth
potential [176]. The growth-restricted fetus/newborn is
characterized by an increased fetal and neonatal mortal-
ity and morbidity [177,178] and an increased risk of clin-
ical disorders in adult life, such as cardiovascular
disease, diabetes and obesity [179,180].
In the prenatal period, differences between GH and
IGF-I are clearly shown. Whereas GH insensitivity, both
in humans and in transgenic mice, have only mild re-
tardation of growth at birth as previously stated [31-35],
IGF-I deficiency in gestational state reveals serious post-
natal growth retardation, as has been reported both in
humans and in transgenic animal models of IGF-I dele-
tion [36-40]. Interestingly, in contrast to growth hor-
mone insensitivity (GHI), the IGF-I deficient animals are
neurologically impaired, as was also reported in a single
patient with a defect in the IGF-I gene [40]. Thus it
appears that IGF-I is necessary for normal brain devel-
opment in uterus while GH insensitivity may be recov-
ered by an intrauterine GH-independent production of
IGF-I [181,182].
Fetal progress is widely controlled by the oxygenated
blood reaching the uterine circulation, the placental
Puche and Castilla-Cortázar Journal of Translational Medicine 2012, 10:224 Page 8 of 29
http://www.translational-medicine.com/content/10/1/224integrity and function, and the fetus ability to get the
required nutrients [183]. It has been estimated that pro-
genitor’s genes account for only 20% of the variation of
human birth weight. Nevertheless, majority of the vari-
ation (62%) is due to the intrauterine environment [184].
Placentas from IUGR pregnancies have been shown to
have poor invasion of the trophoblastic cells into the ma-
ternal decidual tissues, particularly the maternal spiral ar-
teries [185,186]. Studies into the pathological process of
IUGR have pointed to an abnormal placental function as a
common mechanism [187]. However, it is known that the
placental dysfunction is often gradual and it can occur
much earlier than any demonstrable IUGR [188], thus dif-
ficulting the resolution of this hypothesis.
In the same way, IGFs control growth directly, and cir-
culating IGF-I appears to be virtually independent of
fetal GH secretion [182]. However, under this condition,
placental growth hormone may take this role as the
prime regulator of maternal serum IGF-I during preg-
nancy [189], being of particular interest the positive ex-
pression of IGF-IR in placenta [190] and the lower
expression of placental-derived IGF-I during IUGR
[191]. In general, endocrine milieu of the human fetus
with growth retardation is also characterized by low cir-
culating levels of insulin, IGF-I, IGF-II, and IGFBP-3,
and high levels of GH and IGFBP-1 [185,192,193]. At
this point, an elegant study in zebrafish demonstrated
that knockdown of IGFBP-1 significantly alleviated the
hypoxia-induced growth retardation and developmental
delay. And consistently, overexpression of IGFBP-1
caused growth and developmental retardation under
normoxia conditions [194].
In the last years, it is being proposed a role of fetal
programming for an altered GH/IGF axis in IUGR, con-
stituting the so-call Thrifty Phenotype Hypothesis [185],
with an already proven inverse association between IGF-
I levels at 9 months and 17 years. Under this perspective,
GH/IGF-I axis may be programmed early in life. This
fetal programming could be involved in, at least, two
pathological conditions in later life, as insulin resistance
and hypertension. Firstly, children with IUGR show an
impaired GH/IGF-I axis, which might be contributing to
reduced insulin sensitivity and IGF-I resistance, as
higher basal and GH-induced IGF-I levels are required
to achieve a growth velocity similar to that of other chil-
dren, what secondarily leads to a compensatory hyperin-
sulinemia to counteract insulin antagonistic effects of
GH [195] and, an impaired regulation of glucose
transporter-4 expression by insulin in muscle and adi-
pose tissue [196].
In another hand, fetal responses to IUGR-related hyp-
oxia include downregulation of insulin, IGF-I, and IGF-II
and increased expression of inhibitory IGFBPs. Hypoxia
also activates the hypothalamo-pituitary-adrenal (HPA)axis, raising plasma levels of adrenocorticotropic hormone
and cortisol, another mechanism that regulates IGFBP ex-
pression [197]. Moreover, as previously stated, kidney
growth is under IGF-I control; and a reduced IGF action,
parallel to increased cortisol levels, results in a smal-
ler number of glomeruli [198]. Alterations in the
renin-angiotensin system are also frequent, probably
downstream to activation of the HPA axis. These changes
together with compensatory responses for the reduced
kidney function probably account for the predisposition to
adult hypertension.Laron syndrome (LS)
In 1966, Zvi Laron et al. described the first condition of
IGF-I deficiency as a new type of dwarfism indistinguish-
able from genetic isolated GH deficiency, but with unex-
pected high serum GH levels [199,200] and inability to
synthesize IGF-I and other related molecules, as IGFBP-
3 [34,35,201]. This heterogeneous condition was finally
named as Laron Syndrome or primary Growth Hormone
insensitivity (GHI), and it includes: GH receptor defi-
ciency (the most common), GH-GH receptor signal
transduction defect, IGF-I synthetic defect, IGF-I recep-
tor deficiency and IGF-I/IGF-I receptor signal transduc-
tion defects.
Epidemiologically, this pathological entity is closely
related to an ethnic origin (>90% of cases) [19]. Clinic-
ally, overall growth in uterus is slightly shorter at birth
in LS (42–47 cm) than in healthy babies (49–52 cm),
suggesting a potential role of IGF-I in controlling intra-
uterine linear growth [34] as will be discussed ahead.
This condition is more dramatic throughout childhood,
where both skeletal maturation and organ growth are
retarded [19,34,202] probably due to a lower impact of
GH on gestational growth as compared to IGF-I [31-40].
These growth abnormalities in LS patients without IGF-
I substitutive treatment includes postnatal average
growth rates of one-half the expected during the first
years of life [19], a small brain (with prominent forehead,
reduced vertical dimension of the face and hypoplasia of
the midfacies and the nasal bridge), a small heart and
acromicria [203] together with underdevelopment of the
muscular system that delays walking in three-fourth of
patients [204,205], osteopenia at all stages (despite nor-
mal sex hormone status) with increased occurrence of
avascular necrosis of the femoral head [206], impair and
weaken skin, hair and nail growth [207], blue sclera due
to the decreased thickness of its connective tissue, allow-
ing visualization of the underlying choroid [205], a pu-
berty delay from 3 to 7 years [206], retardation in the
maturation of dentition [206] and high-pitched voice
[208]. Of interest, normal reproductive function and be-
havior are widely preserved [202].
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role of IGF-I on brain development and function, as also
will be stated in section “Neurodegenerative diseases”.
Animal models of GHI are available since 1997 [31],
helping us to better understanding the patho-physiological
changes and potentially improved strategies for treat-
ing these patients. Nowadays, this is the unique con-
dition of IGF-I deficiency where rhIGF-I is approved
(as will be stated in “Current therapeutic options”
section).
Chronic liver disease
Cirrhosis is a consequence of chronic and diffuse liver
disease characterized by replacement of liver tissue by fi-
brosis, necrosis and regenerative nodules, leading to loss
of functional liver mass. Cirrhosis is most usually caused
by alcoholism, hepatitis B and C, and fatty liver disease,
among other possible causes [209].
Most common complications of advanced cirrhosis in-
clude jaundice and coagulopathy from hepatocellular in-
sufficiency, gastrointestinal bleeding from esophageal
varices, ascites, hepatorenal syndrome, spontaneous bac-
terial peritonitis, liver-related encephalopathy, and mal-
nutrition [209]. Although survival in patients with
compensated cirrhosis is relatively high (90% at 5 years
after diagnosis), occurrence of complications worsen this
scenario to 30% at 3 years [210,211].
Liver cirrhosis was firstly associated with IGF-I in the
late ‘80s, proposing this hormone as a good indicator for
functional hepatocellular capability [212-214] with a
marked decline from early cirrhosis stages (Child-Pugh A)
[215]. Since then, the idea of liver cirrhosis as a condition
of IGF-I deficiency during adult age has been yearly con-
solidated from a number of publications establishing the
origin of this lack from a decrease in GH receptors seen in
cirrhotic livers [216] and a progressive reduction of liver
synthesis capability from decreased hepatocellular mass in
advanced stages [209]. Furthermore, a marked decline of
IGF-I has also been related to a higher probability of hepa-
tocarcinoma [217] and poorer prognosis in patients re-
quiring liver surgery [218]. As a result IGF-I levels are
considered of prognostic value regarding survival in cir-
rhotic patients [215,218].
The availability of animal models for experimental liver
cirrhosis (carbon tetrachloride, thioacetamide, bile duct
ligation, D-galactosamine. . .) helped us to better elucidate
the role of IGF-I in this pathology. In concrete terms, our
group of work has reported that cirrhotic animals treated
with rhIGF-I showed: increased food ingestion and effi-
ciency with increased nitrogen uptake and balance (result-
ing in an increase in muscle weight) [219], normalization
of intestinal amino acid and sugar absorption [220,221]
(including in animals with advanced cirrhosis and ascites
[222]), glucose metabolism [223], reduced portal pressure,endotoxemia and bacterial translocation [224], improved
osteopenia both in compensated and ascetic cirrhosis
[225,226] and testicular morphology and function [227,228],
recovered somatostatinergic tone [229] with improved
liver function (increased albumin and coagulation factor
levels) and decreased hepatic fibrosis [223]. We have also
reported that the hepatic restoration was associated to
antioxidant, antiapoptotic, antifibrogenic and mitochon
drial-protective effects of IGF-I [230-234].
Aging and age-related diseases
Aging is a universal, intrinsic, irreversible, heterogeneous
and multidimensional process of progressive involution
characterized by a gradual loss of physiological functions
that increases the probability of death. Although related,
longevity is different from aging, since the first one
is simply considered as the length of the life span
independent of the biological aging process. Average life-
span has being (hopefully) continuously growing: from
~27 years in the Greco-Roman era, to ~47 years in
1900, and ~77 years by the end of 20th century [235].
However, it is very interesting that maximum lifespan
(longevity) has not dramatically changed and seems
to rest at about 120 years, despite the increase in the
number of centenarians [236].
Circulating GH and IGF-I levels are maximal during
peripubertal growth and early adulthood; however, they
progressively decline with age [169]. This decline during
human aging is sometimes referred to as somatopause,
in analogy with the menopause and andropause.
Reduced GH/IGF-I secretion in the elderly is believed to
be responsible for or contribute to many symptoms of
aging, including loss of muscle mass, increased adiposity,
reduced bone mineral density, and decline in energy
levels, along with alterations in psychological indicators
of the quality of life [237].
There are diverse theories of aging [238] that basically
point to few broad physiological processes important for
longevity: genetic stability, telomere shortening, stress
resistance and metabolic control. Interestingly, IGF-I is
somehow related to all of them (Figure 3). Firstly, as-
suming that mitochondria are the main source of en-
dogenous free radicals [239,240], it has been previously
reported that species with higher metabolic rates have
shorter maximum lifespan due to superoxide anion rad-
ical accumulation that lead to cell damage, hastening
aging [241]. At this point, we have previously shown that
IGF-I is a main character in restoring mitochondrial dys-
function during aging by increasing mitochondrial mem-
brane potential, reducing oxygen consumption, and
increasing ATP synthesis what in turn minimize the c-
cytochrome release to the cytoplasm and subsequently
promote neural survival by decreasing caspase-induced
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Figure 3 Lifelong beneficial properties of IGF-I. Evolution of IGF-I circulating levels and its pluripotent roles along different stages of human
development and aging.
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oxidant capability in brain cortex and hippocampus was
assessed as improving antioxidant enzymes activities
(superoxide dismutase, catalase and glutathione peroxid-
ase) and parameters of oxidative damage (MDA and
PCC) [55,56]. Thus, by improving mitochondrial func-
tion and decreasing oxidative insults, IGF-I may be pro-
tecting DNA, proteins and lipids.
Secondly, IGF-I has been proposed as an index of
healthy aging, due to the finding that it directly corre-
lates with the leukocyte telomere length [245,246], a bio-
marker of human aging associated with increased risk of
developing vascular diseases, metabolic disorders, and
other age associated phenotypes [247,248].
And thirdly, another aspect where IGF-I may play a
role in delaying aging symptoms is by controlling metab-
olism, together with insulin [249]. The best characterized
intracellular substrates for the insulin and IGF-I recep-
tors are the insulin receptor substrate proteins 1 to 4
[250]. Following tyrosine phosphorylation, each of these
substrates associates with Src homology 2 (SH2)
domains of intracellular molecules to generate down-
stream signals (cfr. Figure 4). The two most important
SH2 molecules at this point are the adaptor moleculeGrb2 and the enzyme PI3K [251,252]. Grb2 links insulin
action to the Ras-MAPK pathway, stimulating cell
growth and differentiation. PI3K, on the other hand, is
responsible for the insulin-like actions of the hormones
by activating Akt/protein-kinase B (PKB) and protein-
kinase C (PKC), which subsequently leads to activation
of p70 S6K and glycogen-synthase kinase 3 [252]. This,
eventually results in stimulation of glycogen, lipid and
protein synthesis, as well as in glucose transporter trans-
location to the plasma membrane with an increase in glu-
cose transport [253]. Importantly, Akt/PKB also phos
phorylates forkhead transcription factors of the FOXO
subfamily, and this leads to their inactivation and reten-
tion in cytoplasm [254,255] resulting in a reduced tran-
scriptional activity [256]. As a final step, depending on the
nature of the activation signal, FOXO can regulate apop-
tosis [257], cell cycle [258], differentiation [256], or the ex-
pression of genes involved in DNA repair [259] and
oxidative stress resistance [260].
In addition, insulin sensitivity normally decreases dur-
ing aging, and insulin resistance is a well established
human risk factor for a variety of illnesses that affect
morbidity and mortality among the elderly, including







































































Figure 4 IGF-I receptor pathway. Activation of IGF-IR leads to a cascade of related molecules involved in previously described actions of IGF-I
(survival, cell growth and differentiation, cytoprotection, glucose metabolism, etc).
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have demonstrated that low doses of IGF-I restored cir-
culating IGF-I levels, which improves insulin resistance
and lipid metabolism in aging rats [55], thus becoming a
potential beneficial agent to prevent insulin resistance-
related pathologies.
As stated before, aging and longevity are different con-
cepts. And this is also evident at the IGF-I function
level. Despite all the beneficial effects of IGF-I described
up to now and the following ones reporting its role in
aging-related pathologies as musculoskeletal, neurode-
generative, cardiovascular diseases, IGF-I has been para-
doxically negatively related to lifespan [266,267],
probably due, at least in part, to its downstream mol-
ecule Akt and its interactions with FOXO, mTOR and
SIRT-1, among others [268,269]. These outcomes de-
mand much more work to elucidate the apparently
contradictory actions of IGF-I on aging and longevity.Cardiovascular diseases (CVD)
Cardiovascular diseases remain the biggest cause of
deaths worldwide, though over the last two decades, car-
diovascular mortality rates have declined in many high-
income countries. At the same time cardiovascular
deaths and disease evolution have increased at an aston-
ishingly fast rate in low- and middle-income countries
due to the increase in obesity, sedentary lifestyles and
unhealthy habits [262].Over the last years, low circulating IGF-I levels have
been correlated with an increased risk for CVD in
humans [270-274]. In cross-sectional studies, low circu-
lating IGF-I levels were found to be associated with
angiographically documented coronary artery disease
[275] and may predict fatal ischemic heart disease [272],
a significantly increased risk of ischemic stroke and con-
gestive heart failure in elderly patients [276,277], as well
as a worse prognosis of recovery after an acute myocar-
dial infarction [278]. Additionally, it has been reported a
positive correlation between circulating IGF-I levels and
both coronary flow reserve [279] and successful cardio-
vascular aging in healthy centenarians [280].
Available data from transgenic mice with liver-derived
IGF-I deficiency clarified that IGF-I deficiency per se can
promote the development of an accelerated cardiovascular
aging phenotype. Particularlly, contractility of cardiac
myocytes is significantly impaired [281,282] together with
a deficient compensatory hypertrophic response, following
experimental aortic constriction [281]. This animal model
also exhibit a dysregulation of Nrf2-dependent antioxidant
responses in the vasculature, which promotes the develop-
ment of marked endothelial dysfunction and endothelial
apoptosis in the presence of increased oxidative stress
[281], mimicking the aging phenotype.
Consistently, a complementary strategy showed that in
aged mice, where IGF-I levels are decreased, cardiac
overexpression of IGF-I significantly improved cardio-
myocyte contractile function [283], attenuating oxidative
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homeostasis, reversing age-related alterations in the ex-
pression of pro-apoptotic proteins, and decreasing the
apoptosis rate [284].
In a similar way, a role for locally produced IGF-I have
also been documented. It was recently demonstrated
that the paracrine IGF-I system confers vasoprotection
and cardioprotection [285] and contributes to the main-
tenance of microvasculature structural and functional in-
tegrity. However, vascular paracrine IGF-I system cannot
compensate for deficiency of circulating IGF-I [286].
Beneficial effects of the IGF-I/IGF-IR system in cardiac
progenitor cells are also starting to be documented. Due
to its great potential, this is a new field that deserves
more recognition and study. The recent identification of a
subpopulation of human cardiac stem cells expressing IGF-
IR and secreting autocrine IGF-I with a secondary thera-
peutic potential for myocardial regeneration [287,288], may
be an important step toward this direction. Among others,
actions of IGF-I on cardiac stem cells include antioxi-
dant effects, upregulation of telomerase activity, a delay
in replicative senescence [288], and migration and ho-
ming of cardiac stem cells facilitating neovascularization
in damaged hearts [287].
Aging is associated with functional and phenotypic
alterations in the microcirculation, including endothelial
dysfunction, oxidative stress, chronic low-grade inflam-
mation, and microvascular rarefaction (reduced number
and combined length of small vessels in a given volume
of tissue) [289]. Our current understanding is that both,
circulating IGF-I levels and locally produced IGF-I, con-
tribute to the maintenance of microcirculation functional
and structural integrity, increasing NO bioavailability, de-
creasing reactive oxygen species (ROS) production, and
exerting antiinflammatory, antiapoptotic, and pro-
angiogenic effects. The mechanisms by which IGF-I
reverses and/or prevents microvascular rarefaction and
improves tissue blood supply are likely multifaceted, and
may involve, among others: 1) Apoptosis, since IGF-I
inhibits oxidative stress-induced apoptosis by preserving
the functional integrity of the mitochondria [56,290]; 2)
Angiogenesis, because IGF-I is known to exert signifi-
cant pro-angiogenic effects, inducing proliferation of
microvascular endothelial cells in culture through
HIF-1α and VEGF [291]; 3) Endothelial cell turnover,
as it was reported that age-dependent impairment of
endothelial progenitor cells is restored by the GH-
mediated increase in circulating IGF-I levels [292];
and 4) Oxidative stress and NO bioavailability, since
age-related oxidative stress and downregulation of
endothelial nitric oxide synthase (eNOS) impair the
bioavailability of NO [293], which is likely to contrib-
ute to decreased microvascular density. Those facts
were confirmed in animal models of IGF-I deficiency as theyoften exhibit increased ROS production and decreased NO
bioavailability, mimicking the vascular aging phenotype
[294]. Of interest, treatment of aged rats with IGF-I was
shown to upregulate eNOS and improve bioavailability of
NO [295], and in vitro experiments in cultured endothelial
cells demonstrated that IGF-I treatment reduce ROS pro-
duction and upregulate eNOS [294].
In the same way, it has been postulated that majority
of these cardiovascular events related to low IGF-I levels
may be due to a possible insulin resistance and acceler-
ated atherosclerosis [296]. Also, the endothelial dysfunc-
tion and subintimal modified lipoprotein deposition are
frequently consequence of oxidative stress [297] and in-
flammatory cells activity [298]. Antioxidant and anti-
inflammatory effects of IGF-I have been documented to
reduce atherosclerotic burden, mainly both via cytokine
response modulation (attenuating IL-6 and TNF-α pro-
inflammatory responses) [299] and/or eNOS activity
regulation [295].
Metabolic syndrome
The metabolic syndrome was defined as a combination
of clinical features that predispose to enhanced CVD
risk, morbidity, and mortality [300]. In some popula-
tions, it is present in ~50% of adults [301]. It is thought
that an important underlying pathogenetic basis for the
metabolic syndrome is insulin resistance and accom-
panying compensatory hyperinsulinemia [301].
Although without total consensus, six components have
been proposed to constitute the metabolic syndrome
[300]: Abdominal obesity (or increased waist circumfer-
ence), atherogenic dyslipidemia (hypertriglyceridemia and
low high-density lipoprotein cholesterol concentrations),
raised blood pressure, insulin resistance with glucose in-
tolerance, pro-inflammatory state (elevated C-reactive
protein) and a pro-thrombotic state (with increased plas-
minogen activator inhibitor-1 and fibrinogen).
On the other hand, similarities between insulin and
IGF-I (molecular homology, shared receptors. . .) point
to the possibility of IGF-I participation in the phenotypic
expression of this disorder [301]. The high insulin levels
could probably cause a downregulation of IGF-I produc-
tion by the liver and other tissues, as a compensatory
homeostatic mechanism, induced most likely through a
differential modulation of IGFBPs production. This
might be responsible for the low IGF-I levels seen in as-
sociation with states of insulin resistance, as the meta-
bolic syndrome [301].
IGF-I’s action on insulin suppression via somatostatine
[1] has been tried in diabetes. In type 1 diabetes, where
IGF-I and IGFBP-3 levels are decreased [302], substitu-
tive rhIGF-I/IGFBP-3 therapy enhances protein [303]
and glucose metabolism by controlling both endogenous
glucose output and peripheral glucose uptake [304]. In
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significantly reduce glucose levels and insulin require-
ment [305] while improving glucose tolerance, hyperin-
sulinemia, and hypertriglyceridemia [306]. Even in
nondiabetic subjects, rhIGF-I enhances insulin sensitiv-
ity, suppresses lipolysis, clears postprandial lipemia, and
increases oxidative and nonoxidative glucose metabolism
[223,307,308]. The higher prevalence of insulin resist-
ance and metabolic syndrome in older people compared
with younger population may also be attributable, at
least in part, to the decline of serum and tissue IGF-I
concentrations with advancing age [55,307]. Reduced
IGF-I levels are independently associated with glucose
intolerance, diabetes, abdominal obesity [309,310] and
atherogenic dyslipidemia [311,312]. Overall, these data
suggest an important and independent role for IGF-I in
protecting against the development of CVD.
Indeed, many of the traditional CVD risk factors, in-
cluding oxidized low-density lipoprotein [313], hyperlipid-
emia (hypercholesterolemia or mixed dyslipidemia) [314]
insulin resistance [309,310,312], diabetes [315], obesity
[309,311], elevated C-reactive protein [316], waist-to-hip
ratio [309], reduced coronary flow reserve [279], smoking
[317], sedentary life [318] and psychological distress [319],
which act via effects on endothelial dysfunction, apoptosis
and impaired endothelial-dependent vascular reactivity,
have been associated with low serum IGF-I levels and
reduced IGF-I and IGF-IR mRNA as well as protein ex-
pression in vascular smooth muscle cells (VSMC) [313].
Initially described as a pro-atherogenic molecule due to
its proliferative role in VSMC, it was further demon-
strated that the effect of IGF-I on VSMC was to com-
pensate for local apoptosis, and that, overall, IGF-I is
not pro-atherogenic in native arteries but anti-
atherogenic [320], mainly through enhanced nitric oxide
production [308]. In addition, IGF-I induces vasodilata-
tion [279,321,322], thereby influencing the regulation of
vascular tone and arterial blood pressure and preserving
coronary flow reserve [279,321], platelet function, and
glucose uptake [323].
Finally, it was recently suggested that IGF-I has signifi-
cant characteristics to be a good marker for the insulin
resistance syndrome and risk of cardiovascular disease,
since logistic regression analysis showed that each unit
increase in log-transformed IGF-I concentrations was
associated with a 90.5% reduction in the risk of meta-
bolic syndrome [274].Neurodegenerative diseases
Neurodegenerative diseases are a heterogeneous group of
disorders from virtually unknown etiology, which eventu-
ally lead to neuronal degeneration and dysfunction. As
described before, since GH/IGF-I axis is involved in manyaspects of brain development, growth and function, their
progressive decrease during aging could be involved in a
variety of human cerebrovascular diseases, comprising
Alzheimer’s disease (AD), vascular dementia (VD), amyo-
trophic lateral sclerosis (ALS) and stroke.
Alzheimer’s disease and vascular dementia are the
most common forms of dementia in elderly [324]. A de-
crease in IGF-I levels in AD and VD has been widely
documented and it may be involved in the development
of neurofibrillary tangles, abnormal amyloid β metabol-
ism and aberrant Tau phosphorylation, cognitive loss,
neural inflammation, oxidative stress or mitochondrial
dysfunction, among others [68,325].
Specifically, IGF-I has been proposed as a physio-
logical regulator of brain amyloid levels [68] by the en-
trance/production through the brain barrier of different
proteins involved in Aβ transport, which eventually
enhances its brain efflux [68,326]. In fact, blockade of
systemic IGF-I action at the choroid plexus was suffi-
cient to induce brain amyloidosis [326].
Another well recognised neuropathological finding in
AD is the accumulation of abnormally hyperphosphory-
lated Tau in degenerating neurons [325]. Based on the
known role of insulin/IGF-I as inhibitors of Tau phos-
phorylation by inhibiting a major Tau kinase, such
as glycogen synthase kinase-β, numerous observations
demonstrated that IGF-I controls the levels of hyper-
phosphorylated Tau in brain [326,327]. Two other patho-
logical processes underlying neuronal decline in AD
are gaining attention: oxidative stress and inflammation
[328,329]. Again, antiinflammatory and antioxidant effects
of IGF-I, together with its antiapoptotic capability, endorse
IGF-I as a suitable candidate for AD treatment. Thus,
although more work in animal models are required, the
available evidence strongly indicates that IGF-I therapy
in Alzheimer’s dementia may address etiopathogenic pro-
cesses and could be a potential candidate for clinical trials.
On the other hand, amyotrophic lateral sclerosis is
the most common motor neuron disorder in human
adults. In this pathology, IGF-I levels diverge between
studies, from increased to decreased IGF-I concentrations
[330-332], probably due to differences in samples origin
(serum/cerebrospinal fluid vs spinal cord/musculoskeletal)
and could be explained as a physiological defensive mech-
anism promoted in response to the neural degeneration
and/or muscle atrophy. Beneficial effects of IGF-I treat-
ment in ALS have been demonstrated both in vivo and
in vitro, from which IGF-I has been postulated as an im-
portant factor for the maintenance and survival of motor
neurons in the spinal cord by activating clue pathways
as PI3K/Akt and p44/42 MAPK [333] and ameliorating
the superoxide effect [334]. Based on the strength of
the pre-clinical evidence, two randomized double-blind
placebo-controlled phase III trials examining the efficacy
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been completed [335,336]; however, the results of
these two trials conflict, concluding, that more complex
studies to set the potential role of IGF-I in ALS disease
are required.
Along with this, cerebrovascular accident (CVA) is
currently the second leading cause of death in the
Western world, ranking after heart disease and before
cancer [337], and experts predict that it is likely to be
soon the most common cause of death worldwide [338].
Studies on patients with ischemic stroke suggest that
high circulating IGF-I levels are associated with neuro-
logical recovery and a better functional outcome [339],
probably due to its neuroprotective and pro-angiogenic
effects. In fact, increased cerebrovacular mortality in
patients with hypopituitarism was documented last cen-
tury [340]. Importantly, as the nervous system ages, there
is also a rarefaction of the microvasculature in different
regions of the brain, as well as alterations in the structure
of the remaining vessels, which have been causally linked
to cognitive dysfunction in older humans [341,342]. This
age-related microvascular rarefaction contributes to a de-
cline in regional cerebral blood flow that reduces meta-
bolic support for neural signaling, especially when
neuronal activity is high. Of great interest, infusion of
IGF-I was shown to elicit a significant (~40%) increase in
cerebromicrovascular density in the adult mouse brain
[343], via stimulation of HIF-1α and its downstream ef-
fector, VEGF.
Menupause and insulin resistance have independently
been involved in the incidence of neurodegenerative dis-
eases [344]. Several studies have pointed to PI3K activa-
tion as a pivotal event for estradiol effects, a common
pathway for IGF-I and insulin [344]. Therefore, it seems
possible that estrogen receptor alpha may interact with
IGF-I/insulin signaling pathways, to promote neuropro-
tective effects in brain. Current investigations are also
evidencing the role exerted by other key signalling mole-
cules, such as glycogen synthase kinase 3 and beta-cate-
nin, in the cross-talk of estrogen receptors and IGF-I
receptors in neural cells [345].
Cognition and memory also decline with age, and
they have been correlated to low IGF-I levels as well
[346-349], through a proposed mechanism that may in-
clude its role in angiogenesis and neurogenesis in the
hippocampus. Interestingly, the phosphodiesterase in-
hibitor Cilostazol (used in peripheral vascular disease
treatment) is able to improve cognitive function in mice
by increasing the hippocampal production of IGF-I
through stimulation of sensory neurons [350].
Musculoskeletal disorders
Aging is associated with a decline in skeletal muscle mass,
sometimes referred to as “sarcopenia of old age”. Thereare several underlying mechanisms that have been impli-
cated in this age-related muscle wasting: decreased protein
synthesis, reduced enzymatic activity (especially in glyco-
lytic and glycogenolytic pathways), depletion in energy
reserves, increased oxidative damage, and changes in ion
content [351], among others. GH and IGF-I have a signifi-
cant anabolic effect on skeletal muscle and so their decline
with aging likely contributes to the decline in muscle
mass. For example, they can promote mitosis, protein syn-
thesis, satellite cell proliferation and nerve sprouting,
while preventing apoptosis [352,353]. However, in general,
tissue responsiveness to IGF-I is altered with aging. Thus,
it was reported that median IGF-I and IGFBP-5 mRNA
levels in resting young muscle are more than twice higher
than those in elderly muscle [354], and aging is associated
with decreases in IGF-IR content and IGF-IR phosphoryl-
ation in muscle [355].
Skeletal health may also be compromised in verte-
brates with reduced GH/IGF-I signaling. Like muscle,
normal aging is associated with both quantitative and
qualitative changes in bone, including alterations in tra-
becular architecture, mineralization, protein content and
the accumulations of microfractures [356]. IGF-I, which
mediates most of the effects of GH on skeletal metabol-
ism, promotes chondrogenesis and increases bone for-
mation by regulating the functions of the differentiated
osteoblasts [357,358]. Furthermore, in fibroblasts, DNA
synthesis and cell proliferation in response to IGF-I de-
crease with elderly [359]. Bone responsiveness to IGF-I
also decreases with aging, requiring higher doses to
reach the same anabolic effect [360]. These studies sug-
gest that low circulating IGF-I bioactivity and/or abnor-
malities of IGF-I signaling in elderly subjects, may play
an important role in age-related sarcopenia and osteope-
nia, where the substitutive IGF-I treatment may be a
suitable therapeutic strategy, although this apparent
IGF-I resistance may dampen this aim.
Other IGF-I deficiency conditions
Renal diseases
As previously stated, the IGF system is involved in nor-
mal kidney development, and age-related dysregulation
of this system may play a role in kidney and vascular dis-
eases, including hypertension [138]. In addition, under
renal dysfunction conditions there are profound changes
in renal responses to GH/IGF-I system as well as in the
circulating levels of these hormones, despite the limited
role of the kidney for removing IGF-I from the circu-
lation (since negligible amounts of the IGFBP-3/ALS/
IGF-I ternary complex crosses the glomerular barrier in
healthy individuals) [361].
In mice with global inactivation of the IGF-I gene, the
proportionally reduced kidney size associates with reduced
glomerular size and decreased numbers of nephrons
Puche and Castilla-Cortázar Journal of Translational Medicine 2012, 10:224 Page 15 of 29
http://www.translational-medicine.com/content/10/1/224[362]. In addition, IGF-I has rapid effects on renal
hemodynamics, including an increased renal blood flow
and glomerular filtration rate [138,141,142]. Furthermore,
both IGF-I and the IGF-IR are expressed in the developing
glomerulus and patterns of expression are disrupted in
animal models and in human examples of renal disease
[140]. Indeed, it has been demonstrated a role of IGF-I
signaling for maintaining glomerular integrity, restoring
podocyte abnormalities, inhibiting podocyte apoptosis,
and alterations in the glomerular basement membrane
and the adjacent endothelial cell layer [140,363].
In humans, IGF-I also increases renal blood flow and
GFR by ~25% and causes volume expansion and sodium
retention by a direct action on the renal tubules, with
stimulation of rennin release and suppression of atrial natri-
uretic peptide secretion [364]. IGF-I administered to GH
deficient rats (or to patients with GH receptor defects) nor-
malizes the low GFR as does GH replacement in GH defi-
ciency. Curiously, the effects of GH on kidney function are
similar to those observed with IGF-I, except that the func-
tional response to GH is delayed several days, correlating
with the secondary increase in serum IGF-I levels, and thus
indicating that the GH effects are mediated by IGF-I. How-
ever, it is noteworthy that GH receptors are present in the
proximal tubule, a site where IGF-I mRNA is not normally
expressed, suggesting that GH also may have direct actions
on tubular function [364].
In another hand, while most reports appear to implicate
IGF-I as a potential mediator of pathological changes in
the diabetic kidney [364,365], IGF-I is also protective
against oxidative stress and apoptosis induced by high
levels of glucose in cultured mesangial cells. This protec-
tion appears to be mediated by Akt/PKB and MAPK sig-
nalling pathways [366], and it has been suggested that
stimulation of this survival pathways may be turned to
therapeutic advantage for protection against cell death
and progression of nephropathy.
Catabolic states
Clinical investigators have shown that IGF-I levels are
often significantly altered in catabolic states, including
the acute postoperative period [367], burn patients [368]
and chronic catabolic illnesses, such as cystic fibrosis
[369] and HIV with wasting [370]. These conditions re-
sult in low IGF-I concentrations, and changes in IGF-I
positively correlate with changes in lean body mass
[369,370], as well as reversal of acute catabolic states is
associated with an increase in IGF-I levels [371,372]. In
clinical use, children with extensive thermal burns who
were treated with IGF-I in combination with IGFBP-3,
presented a reduction in serum levels of IL-1β, TNF-α,
C-reactive protein, α1-acid glycoprotein, and comple-
ment C-3 [299]. In contrast, the serum levels of retinol-
binding proteins, prealbumin, and transferrin wereincreased by the infusion. From these results, authors
concluded that attenuating the pro-inflammatory acute
phase with IGF-I/IGFBP-3 may prevent multiple organ
failure and improve clinical outcomes after thermal in-
jury without any detectable adverse side effects.
Also, when IGF-I was used to monitor total parenteral
nutrition therapy in catabolic patients, the changes cor-
relate with improvements in protein metabolism [373].
Consistently, a close correlation between IGF-I and pro-
tein synthesis in patients with burns was reported [368].
Similarly, extremely low IGF-I levels observed in severe
malnutrition improved with caloric repletion [374].
Current therapeutic options and limitations
The pluripotential roles of IGF-I may explain the inter-
est and wide availability of IGF-I assays from different
laboratories. However, standard methods of IGF-I meas-
urement are not well characterized yet. Recombinant
human IGF-I was first available for experimental therapy
in the late 1980s, what allowed the development of long-
term studies in children with severe primary IGF-I defi-
ciency (defined as a height SDS and IGF-I SDS less
than or equal to −3 and normal or elevated GH levels)
[375]. These studies followed the children for up to
12 years and reported a significant dose-dependent
increase in mean first-year height velocity over baseline
(~3.0 cm/year at baseline, ~8.5 cm/year at first year,
p<0.001) [376-380]. Mean height velocity decreased dur-
ing the subsequent years of treatment, but remained
higher than the pretreatment height velocity for up to
8 years [376]. A complementary aspect of the rhIGF-I
treatment in these patients was an increase in testoster-
one levels, testicular size and stretched penile length,
which indicates a direct effect of IGF-I on sex hormones
and organs in male patients [381].
These studies supported the 2005 US Food and Drug
Administration (FDA) approval of rhIGF-I, being com-
mercially available in 2005 for treatment of patients with
severe primary IGF-I deficiency due to genetic GH re-
sistance from mutations in the GH receptor, defects in
the GH receptor signaling pathway (including STAT5b
gene mutations), mutations in the IGF-I gene, or in rare
patients with GH gene deletions in whom inactivating
antibodies develop to exogenous rhGH [382-384], but
not for other conditions of (secondary) IGF-I deficiency
such as malnutrition, hypothyroidism and chronic ill-
nesses [383]:
 Active or suspected neoplasia.
 Allergy to rhIGF-I (mecasermin, IncrelexW) or any
of its ingredients.
 Chronic illness (i.e. diabetes, cystic fibrosis, etc.).
 Growth failure associated with other identifiable
causes (i.e. Prader-Willi syndrome, Russell-Silver
Table 1 Reported adverse effect during IGF-I treatment







Intracrenial pressure increment 80-120 [378,387]
Lipohypertrophy 60-120 [377,387]
Tonsillar/adenoidal hypertrophy 60-120 [377,387]
Headache and vomiting 80-120 [387]






Subcutaneously, daily, for at least 1 year.
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chromosomal abnormalities).
 Patients with closed epiphyses (for promoting
growth treatments).
By the same time, FDA also approved the use of the
combination of IGF-I and IGFBP-3. Theoretically, it
might be a better choice as a more physiological strategy
(which would require lower doses). However, the results
were not as promising as expected and legal issues led
to its discontinuation. Interestingly, a recent work devel-
oped in two brothers with insulin-like growth factor de-
ficiency, where one was treated with IGF-I plus IGFBP-3
and the other with just IGF-I, showed that both moda-
lities improved determinants of hepatic insulin sensiti-
vity, body composition and linear growth rate; however,
IGF-I alone seemed to be more efficient [385].
A complete review by Laron in 2008 [386] summarizes
the experience by several groups worldwide. The main
conclusions were: 1) The one or two injections regimen
result in the same growth velocity; 2) The growth speed
obtained with IGF-I administration is smaller than that
observed with hGH in children with congenital isolated
GH deficiency; 3) Overdosage of IGF-I causes a series of
adverse effects which can be avoided by carefully monitor-
ing the serum IGF-I and GH levels. The optimal dosing
guidelines are still on debate. Firstly stated on the basis of
IGF-I tolerance, two more recent studies presented at the
International Congress of Endocrinology (2008) showed
the safety and efficacy of both twice-daily (80–120 μg/Kg)
or once-daily (240 μg/Kg) rhIGF-I treatment for primary
IGF-I deficiency [387,388]. Interestingly, it was also
reported a certain degree of heterogeneity in the serum
IGF-I responses, probably influenced on the IGFBP-3
levels [389].
Another disturbing aspects are the difficulties found
when collecting, storing and monitoring IGF-I serum
samples [389,390]. In contrast to GH, circulating levels
of IGF-I remain relatively stable during daytime with
minimum oscillations, being unaffected by meal intake
[391,392]. However, IGFBP-3 levels showed acute
changes with meal intake [391-393], what has direct
consequences on IGF-I bioavailability, and it was
reported a nocturnal decline of IGF-I levels from mid-
night to 4 am [393], probably due to shifts in plasma
volume. Despite this, the lack of any major diurnal vari-
ation in circulating IGF-I levels, combined with the long
half-life of ternary complex constituting IGF-I [393] has
led to the concept that a single measurement of IGF-I
is representative for an individual IGF-I level. On the
other hand, the serum half-life of rhIGF-I is less than
24 hours, what suggests that serum IGF-I monitoring
may be worth for detecting a single missing dose on
the day, but it is not useful for identifying long termtreatment noncompliance [394]. Furthermore, there is
no clear indication to date that routine serum IGF-I
monitoring is informative or useful for children taking
rhIGF-I treatment, as it has not been linked to the occur-
rence of adverse events or efficacy outcomes [387-389].
Safety is the paramount aim when developing new
drugs. In this case, as previously happened with recom-
binant technologies for GH and insulin, IGF-I is a nat-
ural peptide already produced in humans, what facilitates
the elucidation of possible secondary effects due to
rhIGF-I therapy. However, a number of clinical trials
monitoring long-term rhIGF-I treatment have reported
different adverse events [372,377,387-389,395-398], al-
though they were transient, well tolerated and easy man-
aged without treatment discontinuation (Table 1). In
brief, it has been reported episodes of tachycardia
(self-resolved and probably due to the inotropic effect
of rhIGF-I), transient increase of intracranial pressure
with headache and vomiting (consistent with the safety
profile of rhGH treatment), lipohypertrophy at injec-
tion site, tonsillar/adenoidal hypertrophy, facial edema,
arthralgia, myalgia, asthenia, orthostatic hypotension
and hypoglycemia. This decrease in blood sugar could
be a consequence of the insulin like action of IGF-I
per se, and the binding of IGF-I to the insulin recep-
tor. However, a placebo controlled study by Guevara-
Aguirre et al. in 1995 reported no statistically significant
difference in the frequency of hypoglycemia in those who
received IGF-I vs. placebo for 6 months (86% in IGF-I
group vs. 67% in the placebo group) [379]. Interestingly,
as previously stated by Laron [386], doses lower than
60 μg/Kg/day did not show these described adverse
effects, both in human clinical trials [398,399] and in ani-
mal experimental models [55,56,219-221,223].


















AIDS muscle wasting [411]




X-linked severe combined immunodeficiency [418]
Hearing loss prevention [414]
Anorexia nervosa [420]
Retinopathy of prematurity [422]
rhIGF-I replacement therapy may be recommended only to restore IGF-I
deficiency conditions. In consequence, despite the number of proposed
pathological conditions that may benefit from rhIGF-I treatment, up to date,
only those in the white have been well characterized. Conditions in clear grey
are supported by a wide body of evidence which render these circunstances
prone to be classified as the first group. Dark grey are conditions that may
need more research in order to adequately propose the IGF-I treatment as a
proper strategy.
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Laron syndrome is the significant increase in body adi-
pose tissue (to double or triple the normal values) con-
comitantly with the increase in growth [400] although,
due to the underdevelopment of the muscular and skel-
etal systems, body mass index did not accurately reflect
the degree of obesity. From these data, authors concluded
that IGF-I, similar to insulin, exerts an adipogenic effect.
However, another study in insulin resistance, reported a
reduction in both intramyocellular lipids and intrahepatic
fat in a patient treated with rhIGF-I/IGFBP-3 (together
with a post-treatment normalization of % HbA1C value)
[401]. These data, although very preliminary, may indi-
cate different mechanistic pathways by which IGF-I
controls lipid metabolism.
Consistently, despite these known effects, we still must
be alert due to the reported potential role of IGF-I in
neoplasias development (a recommended review is avail-
able at ref. [402]). Fortunately, a recent study shed some
light on this topic by reporting the malignancies occur-
rence in patients with congenital IGF-I deficiency and
insensitivity to GH. They found that this condition
seemed to be protective against future cancer develop-
ment, but more interesting, even when treated with
IGF-I [403]. Furthermore, no current data in the litera-
ture suggest the malignant transformation of a normal
cell in association with IGF-I administration, what may
reassure possible concerns about its long-term safety
and use in replacement therapies.
Nowadays, rhIGF-I therapy is also being tested or
proposed in other pathological conditions as chronic
liver disease, insulin resistances/hyperinsulinemia,
diabetes, neurological disorders (Alzheimer’s disease
and amyotrophic lateral sclerosis) and stroke, cysticfi-
brosis, wound healing, AIDS muscle wasting and HIV-
associated adipose redistribution syndrome, burns,
osteoporosis, Crohn’s disease, Werner syndrome, X-
linked severe combined immunodeficiency, myotonic
muscular dystrophy, hearing loss prevention, spinal
cord injury, cardiovascular protection, anorexia ner-
vosa, fetal growth restriction and prevention of retinop-
athy of prematurity [182,303-306,384,399,401,404-423],
although some of the treatment’s contraindications may
limit its potential applicability (Table 2).
Nonetheless, in spite of the great amount of data
obtained from these studies, there is still a necessity for
further studies to either elucidate the right doses to
achieve the expected results, clarify the rhIGF-I therapy
effectiveness or even exclude any potential adverse
event. For example, the effect of rhIGF-I in chronic liver
injury (20 μg/Kg/day with dose escalation up to 50–
100 μg/Kg/day for 4 months) was mainly reduced to an
increase in albumin levels [399], probably due to the low
number of subjects and treatment guidelines, which couldnot achieve normal IGF-I values, as was also reported in
a recent study [387] where doses by 40 μg/Kg/day did
were not able to normalize serum IGF-I.
In our experience, the most important goal is to
prove the presence of IGF-I deficiency. However, in
some cases like compensated liver cirrhosis, IGF-I cir-
culating levels are normal, but if low doses of this hor-
mone are administrated, many beneficial effects are
induced [219-221,223,225,228,232]. This finding sug-
gests that the bioavailability of IGF-I is reduced from
early stages of liver disease. However, without hepato-
pathy, IGF-I levels and bioavailability are not dimin-
ished. Thus, IGF-I treatment failed to induce the
desired effects, like was reported in a model of testicu-
lar dysfunction secondary to epinephrine intra-scrotal
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condition of IGF-I deficiency) [424].
At this point, it is also crucial to state that testicular
dysfunction was only restored when it was associated to
IGF-I deficiency conditions, since IGF-I treatment of
rats with testicular damage secondary to epinephrine
intra-scrotal injections (but without liver cirrhosis or any
other condition of IGF-I deficiency) was not able to ad-
equately recover their morphology and function.
On the other side, therapeutic use of rhIGF-I has been
debated in ALS, since a Cochrane systematic evidence
review found that the available randomized placebo con-
trolled trials [335,336] did not permit a definitive assess-
ment of its clinical efficacy [407], with just a small
significant benefit in favor of recombinant IGF-I, which
clinical relevance is unclear. The authors concluded that
more research is needed, noting that one trial is in pro-
gress, and they recommended that future trials may in-
clude survival rates as another outcome measure.
And thirdly, although Rosenbloom [384] stated that the
rhIGF-I insulin-sensitizing effect may be beneficial for dia-
betic patients to reduce hemoglobin A1C levels, there are
no current ongoing clinical trials because of concern about
risk of retinopathy and other complications [425], thus
limiting the theoretically wide spectrum of potential IGF-I
treatment indications.
Conclusions
Briefly, IGF-I deficiency states –as it is the case with
every other hormone- produce effects that culminate
in recognizable syndromes with significant clinical
consequences. Until now, the best known conditions of
IGF-I deficiency are: Laron Syndrome, in children;
advanced liver cirrhosis, in adults; and aging including
cardiovascular and neurological diseases associated to
aging. More recently, intrauterine growth restriction
seems to appear as another state of IGF-I deficiency. In
these four conditions, the replacement therapy can
logically induce beneficial actions. Apart from these,
many other diseases have been recently proposed to be
either consequence or cause of both a systemic or par-
tial IGF-I deficiency. However, more in-depth studies
are needed to properly characterize these potential
new conditions of IGF-I deficiency and their future
clinical perspectives.
On the other hand, the multiple physiological proper-
ties of IGF-I may generate excessive prospects if basic
concepts about this topic are not adequately considered:
1. IGF-I is a closed regulated hormone. Its therapeutic
applications should, in principle, be limited to restore
physiological levels, but not over its normal range, as
it is the usual practice in endocrinology diseases
(hypothyroidism, diabetes, etc.).2. Exogenous administration of IGF-I in conditions
without IGF-I deficiency, usually responds to an
attempt to exploit its anti-inflammatory,
hematopoietic, antioxidant, metabolic or anabolic
properties. However, despite the limited results of
these strategies, it may entail obvious risks. In the
best of cases, these strategies would require prudence
and short periods of treatment, as in the
corticotherapy.
3. Low doses of IGF-I seem to be able to restore
circulating levels of this hormone promoting
beneficial effects without secondary effects (including
hypoglycemia). Secondary adverse effects from IGF-I
therapy were reported after administration of doses
higher than 60–80 μg/Kg/day.
4. The axis GH/IGF-I is claiming a particular
physiological understanding. Usually IGF-I deficiency
is associated to “GH resistance” or “GH insensibility”
states. IGF-I replacement therapy induced a
restoration of the altered GH/IGF-I axis by reducing
circulating GH levels and improving
somatostatinergic tone. Thus, IGF-I therapy would
need to be considered as a different strategy from
GH treatment, avoiding past inadequate procedures
when both GH/IGF-I therapies were considered
equivalent.
5. Finally, a concern about the potential relationship
between IGF-I and cancer is an awkward issue that
may require a deeper approach. For instance, a
question may arise: are the higher circulating IGF-I
levels a marker or a causal factor? In our experience,
IGF-I at low doses is a cytoprotective factor that,
exerting effective mitochondrial protection, anti-
inflammatory and antioxidant activities, could
prevent oncogenesis and cancer development by
acting in the earliest stages of these pathogenic
mechanisms. In addition, despite permanent
reservations relating cancer and IGF-I, no current
data suggest an IGF-I related malignant
transformation from a normal cell.
In conclusion, on the basis of the available evidence,
and despite the current limitations in this matter, it
seems reasonable that IGF-I therapies may be designed
only to restore its physiological levels as a replacement
treatment, but never elevating IGF-I levels above its
upper normal range.
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